Who We Are

NeuroTrauma Sciences (NTS) is a biopharmaceutical company focused on developing neuroprotective and neurorestorative agents to treat brain injury including stroke, concussion, and the complications of traumatic brain injury (TBI).

What We Do

When someone suffers a serious brain injury there are currently no drugs available to alleviate the cognitive, functional, and neurobehavioral effects.

NTS is developing a portfolio of products designed to address these life impairing damages.

Our Team

Carl Long

Carl Long

Chief Executive Officer

Read bio >

Judith Hedstrom

Judith Hedstrom

Vice President of Operations

Read bio >

Brent Miller, Ph.D., PMP, CA-AM

Brent Miller, Ph.D., PMP, CA-AM

Vice President of Product and Portfolio Management

Read bio >

Dean Murphy, RAC

Dean Murphy, RAC

Vice President of Regulatory Affairs and Quality Assurance

Read bio >

Warren Wasiewski

Warren Wasiewski

Vice President of Research and Development

Read bio >

David Poulsen, Ph.D.

David Poulsen, Ph.D.

Chief Science Advisor

Read bio >

David H. Fater

David H. Fater

Chief Administrative Officer & Finance Director

Read bio >

Our Investors

NeuroTrauma Sciences LLC is a funded, privately held company.
Additional information on our investors may be made available upon request.

Contact Us